Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

UK Cost Agency Rejects Drugs From Bristol-Myers Squibb Co, Roche Holding AG And AstraZeneca PLC-Reuters


Thursday, 31 Jan 2013 07:01pm EST 

Reuters reported that Britain's healthcare cost watchdog NICE said on February 01, 2013 it was not able to recommend a new diabetes drug from Bristol-Myers Squibb Co and AstraZeneca PLC, and has asked for more information from the companies. The National Institute for Health and Clinical Excellence (NICE) has been considering Forxiga, or dapagliflozin, as an add-on therapy for use with other medicines, including insulin. NICE, which decides if drugs should be paid for on the state health service, also said it had issued draft guidance not recommending Roche Holding AG's Avastin for ovarian cancer. The agency has already rejected Avastin in other tumour types. 

Company Quote

49.99
-0.05 -0.10%
21 Aug 2014